Pre-Submission Review for Infectious Disease Journals: What Reviewers Expect

Infectious disease research spans multiple publication categories - clinical journals, microbiology journals, virology journals, and broad biomedical journals that cover major outbreaks and pandemics. Targeting the right venue is the first decision, and it has a large effect on your chances of success.

This guide covers what the top infectious disease journals prioritize, what causes rejection at each tier, and how pre-submission review should be structured for ID manuscripts.

The Infectious Disease Journal Market

The infectious disease publication space breaks into three main categories.

Clinical ID journals (Lancet Infectious Diseases, Clinical Infectious Diseases, Journal of Infectious Diseases) focus on patient outcomes, epidemiology, treatment trials, and public health implications. The primary currency is clinical data. Reviewers are infectious disease clinicians and epidemiologists who evaluate study design, statistical approach, and clinical relevance.

Microbiology and host-pathogen journals (Cell Host & Microbe, PLOS Pathogens, mBio, Journal of Virology) focus on mechanistic science - how pathogens infect, replicate, evade immunity, and cause disease at the molecular and cellular level. Reviewers are microbiologists, virologists, and immunologists who evaluate mechanistic depth and experimental rigor.

Broad biomedical journals (Nature, Science, Cell, NEJM, JAMA, Lancet) publish infectious disease work that meets their general standards for major advance. A paper that fundamentally changes understanding of how a pathogen causes disease, or a clinical trial with major practice implications for a high-burden infection, belongs here. These journals aren't ID-specific - they require broad significance beyond the ID field.

What Lancet Infectious Diseases Looks For

Lancet Infectious Diseases (IF 31.0) is the highest-impact dedicated clinical ID journal. It wants research that changes clinical practice or public health policy.

Reviewers at Lancet ID are evaluating: Is this patient population representative enough to generalize the findings? Is the statistical approach appropriate for the study design? Does the finding actually change what clinicians should do, or does it confirm something that was already known? Is the public health relevance stated explicitly?

Papers that succeed at Lancet ID typically have multicenter or multinational patient data, clear primary endpoints, and conclusions that directly address clinical management. Single-center retrospective analyses, even of interesting clinical questions, often get redirected to Clinical Infectious Diseases or other second-tier venues.

What Microbiology Journal Reviewers Expect

For journals like PLOS Pathogens, mBio, and Cell Host & Microbe, reviewers' expectations are different from clinical journals.

Mechanistic completeness. Describing that a pathogen protein does something to host cells isn't enough. Reviewers want to know the mechanism - which host protein does it interact with, how does it disrupt host signaling, and what is the functional consequence for infection outcome? Genetic approaches (knockouts, complementation, structure-function mutations) that establish mechanism are expected.

Appropriate infection models. For claims about how a pathogen causes disease, the infection model needs to be appropriate. Primary human cells or organoids are stronger than immortalized cell lines. Animal models that recapitulate the human disease are stronger than models where the pathogen doesn't naturally infect the animal.

Novelty relative to the recent pathogen-specific literature. Reviewers at microbiology journals are specialists in specific pathogens. They know the field and will check novelty claims carefully. A mechanism described for influenza that's already been shown for RSV needs to explain why the finding is non-obvious given the prior work.

Pre-Submission Review for ID Manuscripts

Pre-submission review for an infectious disease manuscript should address the specific questions reviewers at your target journal will ask.

For Lancet ID submissions: Is the patient data strong enough to support the practice implication? Is the statistical analysis appropriate and pre-specified? Are the clinical conclusions supported by or overstating what the data show?

For microbiology journals: Is the mechanistic evidence complete? Are there missing controls or alternative interpretations that a reviewer would flag? Is the infection model appropriate for the claims made?

A Manusights reviewer with publications in ID-relevant journals will apply these standards to your manuscript before you submit. See our pre-submission review service for details. The AI Diagnostic gives a fast structural and scientific assessment in 30 minutes. If you're revising after a rejection, our revision guide covers how to address reviewer feedback systematically.

What teams underestimate in infectious disease submission planning

Most groups don't lose time because the science is weak. They lose time because the submission sequence is sloppy. A manuscript goes out with one unresolved weakness, gets predictable reviewer pushback, then the team spends 8 to 16 weeks fixing something that could have been caught before first submission. That's why a good pre-submission pass pays for itself even when the paper is already strong. You aren't buying generic feedback. You're buying a faster path to a decision that can actually move your project forward.

A practical pre-submission workflow that cuts revision cycles

Use a three-pass process. Pass one is claim integrity. For each major claim, ask what figure carries it and what competing explanation still survives. Pass two is reviewer simulation. Force one person on your team to argue from a skeptical reviewer position and write five hard comments before submission. Pass three is journal-fit edit. Tighten title, abstract, and first two introduction paragraphs so the paper reads like it belongs to that exact journal, not just any journal in the field. Teams that do this often reduce first-round revision scope by one-third to one-half.

Where strong manuscripts still get rejected

A lot of rejections come from mismatch, not low quality. The data may be strong, but the manuscript promises more than it proves. Or the discussion claims broad relevance while the experiments only establish a narrow result. Another common issue is sequence logic. Figure 4 may be decisive, but it's buried after two weaker figures, so reviewers form a negative opinion before they reach the strongest evidence. Reordering figures and tightening claim language sounds minor, but it changes reviewer confidence quickly.

Example timeline from submission to decision

Here's a realistic timeline from teams we see often. Week 0: internal final draft. Week 1: external pre-submission review with field specialist comments. Week 2: targeted edits to claims, methods clarity, and figure order. Week 3: submit. Week 4 to 6: editor decision or external review invitation. Week 8 to 12: first decision. Compare that with the no-review path, where first submission leads to avoidable rejection and the same manuscript isn't resubmitted for another 10 to 14 weeks. The science hasn't changed, but total cycle time has.

Trade-offs you should decide before paying for review

Not every manuscript needs the same depth of feedback. If your team has two senior PIs with recent publications in the same journal tier, a focused external review may be enough. If this is a first senior-author paper, or the target journal is above your group's recent publication history, you need deeper critique on novelty framing and expected reviewer asks. Also decide whether speed or certainty matters more. A 48-hour light pass can catch clarity issues. A 5 to 7 day field-expert review is better for scientific risk.

How to judge feedback quality

High-value feedback is specific and testable. It references exact claims, figures, and likely reviewer language. Low-value feedback stays at writing style level and never addresses whether the central claim will hold under external review. After you receive comments, score each one using a simple rule: does this comment change the acceptance odds if we fix it? If yes, prioritize it. If no, park it. This keeps teams from spending three days polishing wording while leaving one fatal mechanistic gap untouched.

Internal alignment before submission

Get explicit agreement from all co-authors on three points: first, the single-sentence take-home claim; second, the strongest evidence panel; third, the limitation you'll acknowledge without hedging. If co-authors can't align on those points, reviewers won't either. This short alignment meeting usually takes 30 to 45 minutes and prevents messy, last-minute abstract rewrites. It's also the moment to confirm who will own response-to-reviewers drafting so revision doesn't stall later.

If rejection happens anyway

Even with great prep, rejection still happens. The key is whether you can pivot in days instead of months. Keep a fallback journal ladder ready before first submission, with format requirements, word limits, and figure count already mapped. Keep two abstract versions: one broad and one specialty-focused. After decision, run a 60-minute debrief, label each comment as framing, evidence, or fit, then rebuild submission strategy around that label. If you need support on the next step, see manuscript revision help, response strategy, and the AI diagnostic for a quick risk scan.

Real reviewer-style checks you can run tonight

Take one hour and run this quick audit. First, print your abstract and remove all adjectives like significant, important, or novel. If the core claim still sounds strong, you're in good shape. If it collapses, your argument is too dependent on hype language. Second, ask whether every figure has one sentence that starts with "This shows" and one that starts with "This doesn't show." That second sentence keeps overclaiming in check. Third, verify that your methods section names software versions, statistical tests, and exclusion rules. Missing details here trigger trust problems fast.

Data presentation details that change reviewer confidence

Reviewers notice presentation discipline right away. Keep axis labels readable at 100 percent zoom. Define all abbreviations in figure legends even if they appear in the main text. Use consistent color mapping across figures so readers don't relearn your visual language each time. If one panel uses blue for control and another uses blue for treatment, reviewers assume the manuscript wasn't reviewed carefully. Also report denominators clearly, not just percentages. "43 percent response" means little without n values.

Co-author process and accountability

A lot of submission friction is organizational. Set a hard owner for each section, not a shared owner. Shared ownership sounds polite but usually means no ownership. Set a 24-hour turnaround rule for final comments in the last week before submission. After that window, only factual corrections should be accepted. This avoids endless style rewrites. Keep one decision log with date, decision, and rationale. When disputes return three days later, you can point to prior agreement and keep momentum.

Budgeting for revisions before they happen

Plan revision resources before first submission. Reserve protected bench time for one to two confirmatory experiments, and set aside analyst time for replotting figures quickly. Teams that treat revision as a surprise lose four weeks just finding bandwidth. Teams that plan for it can turn a major revision in 21 to 35 days, which editors remember. Fast, organized revision signals that the group is reliable and that the project is being managed with care.

Sources

• Clarivate Journal Citation Reports 2024: Lancet Infectious Diseases 31.0, PLOS Pathogens 4.9, mBio 4.7
• Lancet Infectious Diseases submission guidelines: thelancet.com/journals/laninf